title: Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy.
abstract: BACKGROUND
  Cardiac allograft vasculopathy, a diffuse and accelerated form of arteriosclerosis, is a major cause of graft loss or heart transplant recipient death after the first transplant year. This study examined the effects of depleting host CD8 + T lymphocytes on the development of cardiac allograft vasculopathy in miniature swine.
  
  
  METHODS
  Cardiac allografts were heterotopically transplanted across a major histocompatibility complex class I barrier in partially inbred miniature swine and monitored for rejection by serial biopsies, electrocardiograms, and echocardiograms. Four control animals received cyclosporine on postoperative days 0 to 11. Another four miniswine were given 14.5 mg/kg of 76-2-11 (a mouse anti-swine CD8 monoclonal antibody) on postoperative day 0, in addition to a 12-day course of cyclosporine. Host CD8+ T cells and circulating 76-2-11 monoclonal antibodies were monitored by flow cytometry.
  
  
  RESULTS
  As compared with cyclosporine-treated control animals, swine receiving 76-2-11 demonstrated near-complete depletion of peripheral CD8+ T cells by postoperative day 2, which persisted for 14 to 18 days. Mean allograft survival of the antibody-treated group and the control group was not statistically different (33 days versus 39 days, respectively) and both groups demonstrated severe interstitial rejection at necropsy. Control animals demonstrated florid intimal thickening of large and small arteries at necropsy. However, swine treated with 76-2-11 showed no intimal proliferation.
  
  
  CONCLUSIONS
  Depletion of host CD8+ T cells prevents or delays the development of intimal proliferation in miniature swine. CD8+ lymphocytes play an important role in the early development of cardiac allograft vasculopathy in large animals.
authors.affiliation: Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Allan
authors.forename: J K
authors.initials: JK
authors.lastname: Choo
authors.forename: L
authors.initials: L
authors.lastname: Vesga
authors.forename: J S
authors.initials: JS
authors.lastname: Arn
authors.forename: M R
authors.initials: MR
authors.lastname: Pins
authors.forename: D H
authors.initials: DH
authors.lastname: Sachs
authors.forename: J C
authors.initials: JC
authors.lastname: Madsen
mesh_terms: D000818:Animals; D017849:Animals, Inbred Strains; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D003327:Coronary Disease / Q000209:etiology / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000473:pathology; D016572:Cyclosporine / Q000627:therapeutic use; D016027:Heart Transplantation / Q000009:adverse effects / Q000276:immunology*; D018655:Lymphocyte Count; D013552:Swine; D013556:Swine, Miniature / Q000235:genetics; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D016572:Cyclosporine